[Therapy of ankylosing spondylitis].
Due to the unknown etiology of the ankylosing spondylarthritis up to now a causal therapy is not possible. By complex methods of treatment, consisting of chemo- and physiotherapeutic measures we succeed in controlling the course of the disease in as far that the most severe morphological lesions may be prevented. Decisive is the use of a basis therapeutic, in which case chlorochine has been proved favourable. In the last years by optimum dispensary care of these patients with regular controls of the course and controls of the therapy as well as use of all possible rehabilitation measures the premature rate of invalidisation could be reduced from about 50% to 10%. When the disease is recognized in the prodromal phase there exists established hope of preventing severe morphological lesions.
D002738:Chloroquine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D008134:Long-Term Care; D010653:Phenylbutazone / Q000627:therapeutic use; D026741:Physical Therapy Modalities; D013167:Spondylitis, Ankylosing / Q000188:drug therapy / Q000517:prevention & control / Q000628:therapy*; D013997:Time Factors
D002738:Chloroquine; D010653:Phenylbutazone
Therapie der Spondylitis ankylosans.